Abstract #0552

Prostate Cancer Detection Rate: MRSI Directed TRUS Biopsy Versus Increasing Number of Cores in Clinically Challenging Group of Men with PSA in the Gray Zone of 4-10 Ng/ml

Durgesh Kumar Dwivedi¹, Tarun Javali², Rajeev Kumar², Sanjay Thulkar³, Sanjay Sharma³, Amit K. Dinda⁴, Naranamangalam R. Jagannathan¹

¹Department of NMR & MRI Facility, All India Institute of Medical Sciences, New Delhi, Delhi, India; ²Department of Urology, All India Institute of Medical Sciences, New Delhi, Delhi, India; ³Department of Radio-diagnosis, All India Institute of Medical Sciences, New Delhi, Delhi, India; ⁴Department of Pathology, All India Institute of Medical Sciences, New Delhi, Delhi, India

Raised serum prostate specific antigen (PSA) may not reflect the presence of prostate cancer (PCa) and transrectal ultrasound (TRUS) has limited sensitivity in PCa detection. MRSI has the potential to detect PCa based on metabolic differences. We performed a retrospective case controlled study on 278 men prior to biopsy with PSA in the range of 4-10 ng/ml. Our study revealed that MRSI directed TRUS biopsy increases PCa detection rate (2.9 times) compared to standard TRUS guided core (6 or 12) biopsy in patients with PSA in the range of 4-10 ng/ml.